Key takeaways
- Oral minoxidil is prescribed off-label for hair loss; its established tablet indication is severe hypertension. Minoxidil product information.
- A 2024 trial did not show overall superiority over topical minoxidil in men with pattern hair loss. Randomised trial.
- Unwanted hair growth elsewhere and headache were common in the oral-treatment group. Study results.
- Tablets can affect heart rate, blood pressure and fluid balance. A smaller prescription does not remove the need for medical assessment. Product warnings.
Scalp irritation or difficulty keeping up with topical treatment can prompt a discussion about tablets. Lonitab is one minoxidil tablet brand. The 2024 comparison below tested the oral and topical routes at a single specialist clinic in Brazil; the participants were men aged 18 to 55. It cannot establish which route is best for every person with hair loss. Trial design.
Are tablets better than topical minoxidil?
They can be an option for selected patients, but they are not a proven upgrade for everyone.
A Brazilian trial enrolled 90 men and compared oral and topical minoxidil over 24 weeks. Oral treatment did not demonstrate superiority on the study’s primary hair-density outcomes. A photographic assessment favoured oral treatment at the crown, but not the front of the scalp. Sixty-eight participants completed the trial. JAMA Dermatology study.
Participants received either oral minoxidil with a placebo scalp solution, or topical minoxidil with a placebo tablet. The primary outcome was the change in terminal hair density at the front and crown. Total density and photographic assessments were secondary outcomes. The crown-photo result does not change the overall finding, and a 24-week study in men cannot settle questions about women, other causes of hair loss or long-term safety. Trial methods and outcomes.
| Consideration | Topical minoxidil | Oral minoxidil |
|---|---|---|
| How it is used | Applied to the scalp | Taken as a tablet |
| Practical concern | Application routine and scalp irritation | Systemic exposure and medical monitoring |
| Reason to discuss it | A scalp-directed approach | Topical treatment is unsuitable or difficult to sustain |
Why does the prescriber ask about your heart?
Minoxidil tablets are a blood-pressure medicine, even when prescribed for hair loss.
The tablet product information warns about fluid retention, an increased heart rate and pericardial effusion, which is fluid around the heart. It describes treatment for severe hypertension; its doses and accompanying medicines should not be copied into a hair-loss plan. Loniten product information.
The Loniten label describes salt and water retention that can worsen heart failure. It calls for monitoring of body weight, fluid and electrolyte balance, with particular attention to people with impaired kidney function. Other blood-pressure-lowering medicines can add to minoxidil’s effect. Tell the prescriber about heart or kidney disease, fainting, low blood pressure, swelling and all medicines before treatment. The clinician sets the examination, blood-pressure checks and any further tests for the individual hair-loss prescription. Monitoring and interactions.
Seek urgent medical care for chest pain, breathlessness or fainting. Report new swelling or a persistently racing heartbeat promptly.
How should progress be assessed?
Agree when to review the treatment, using consistent photographs and the clinician’s assessment.
Bring earlier photographs and a record of how long and how regularly you used the previous treatment. Tell the clinician whether irritation, shedding, no regrowth or an impractical routine made you stop. Compare photographs at the agreed review; day-to-day shedding alone is insufficient.
Unwanted hair growth was reported by 22 of the 45 men assigned oral minoxidil in the trial, or 49%. Headache affected 6 of 45 (14%). Record any unwanted hair growth or headache for the follow-up appointment. Trial adverse effects.
The Loniten hypertension label describes lengthening, thickening and darkening of fine body hair, often first on the face. It reports onset after 3 to 6 weeks and a return towards the pre-treatment state one to six months after stopping. Those observations come from its hypertension use; they cannot give an individual hair-loss patient a precise timetable. Hypertrichosis information.
Raise unwanted facial hair at the review; the Vaniqa guide discusses that separate concern. The finasteride versus dutasteride article covers scalp hair-loss treatment through a different mechanism.
Do and don’t
Do:
- Tell the prescriber about cardiovascular symptoms and other medicines.
- Before buying ongoing treatment in South Africa, agree who will manage follow-up and side effects.
- Ask the pharmacist to check the ingredient, tablet strength and formulation against your prescription, even with a familiar brand or overseas approval.
Don’t:
- Split higher-strength tablets into an improvised hair-loss regimen.
- Assume an oral medicine is safer because it avoids scalp irritation.
